Navigation Links
Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule

MADISON, Wis., March 22, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) announced today that their two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) to substantiate CDI's iCell® Cardiomyocytes as a predictive tool for assessing the potential cardiotoxic effects of developing drug candidates was completed early and is now transitioning into a standard supply agreement.  Moving forward, iCell Cardiomyocytes, induced pluripotent stem cell (iPSC)-derived human heart cells, will be incorporated into Roche's drug development decision-making process.

CDI and Roche initiated their collaboration in March 2009 to interrogate CDI's iCell Cardiomyocytes against a well-categorized compound reference set intended to test the ability of the cardiomyocytes to predict drug-induced, potentially life-threatening, cardiac arrhythmias. These studies included longitudinal genetic and molecular characterizations of the cardiomyocytes and assessment of their performance across a variety of established and novel testing platforms designed to detect possible cardiotoxic effects of developing compounds early in their development cycle.  Multiple publications based on this research are in preparation for submission to peer-reviewed journals.

"This transition to a standard supply agreement is an important milestone for CDI," said Chris Parker, Chief Commercial Officer of CDI.  "CDI and Roche have developed and demonstrated, respectively, a more efficient tool to reveal potential cardiotoxicity in their drug development candidates.  iCell Cardiomyocytes have proven to provide value to pharmaceutical drug discovery and development."

Robert Palay, CEO and Chairman of the Board of CDI, added, "We have developed iCell Cardiomyocytes as a cardiac cell model that truly reflects human biology. In addition, we have developed a manufacturing process that enables us to reliably deliver the cells in the quantity, quality and purity that our customers require to successfully accomplish their drug discovery and toxicity testing research.  We look forward to continuing our relationship with Roche and enabling them to discover future drug candidates that could improve human health."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications.  CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools.  In addition, it is the leader in iPS cell technology, the production of pluripotent stem cell lines from adult tissue.  CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison.  CDI's facilities are located in Madison, Wisconsin. See

SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
2. SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011
3. Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
4. Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF
5. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
6. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
7. Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio
8. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
9. Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
10. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
11. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... Francisco, California (PRWEB) , ... November 27, 2015 , ... ... Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's ... at the Canterbury House at the University of Michigan in Ann Arbor. The According ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... substance abuse located in central Michigan, have come together on Thanksgiving Day to ... produced video, available for viewing on the Serenity Point YouTube channel, patients displayed ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record ... performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the ... to rebuild lives and it’s an honor to have served all of these women.” ...
Breaking Medicine News(10 mins):